Mevo, a leading Brazilian healthtech specializing in e-prescriptions, has successfully secured US$18 million in a new funding round. The investment was led by Prosus and saw significant participation from existing shareholders, including Matrix and Jefferson River. This capital infusion follows a recent Series B round, underscoring strong market confidence in the company's platform and strategic vision.
Modernizing Brazil's Healthcare Landscape
Founded in 2017, Mevo emerged to address a significant inefficiency within Brazil's healthcare system, where billions of handwritten prescriptions created barriers to integrated care. The company's digital platform modernizes this process, providing a streamlined and secure alternative for medical professionals. This innovation serves as the foundation for a more connected and efficient patient experience across the country.
The company's growth is anchored by a three-pronged strategy focused on distinct market segments. Its core offering provides e-prescription services to both large institutions and individual doctors. Additionally, its Mevo Shop portal empowers patients with online pharmacy fulfillment, while a dedicated vertical offers solutions for pharmaceutical industry partners.
Strategic Expansion and Market Penetration
Mevo has established a formidable presence within Brazil's institutional healthcare sector, a key element of its market leadership. The platform is integrated into over 1,100 healthcare facilities and seven major health insurance providers, covering a significant portion of the private market. Its adoption by nine of the nation's top ten hospitals further solidifies its position as a trusted partner.
Beyond large institutions, the company has rapidly expanded its reach among individual practitioners. Following the strategic acquisition of competitor Receita Digital, Mevo increased its base of individual prescribers by five times. This move has significantly broadened its user network and strengthened its footprint across the entire healthcare ecosystem.
In parallel, Mevo has advanced its patient-centric services through the growth of its pharmacy and fulfillment vertical. The Mevo Shop platform now connects with 11 major pharmacy chains, encompassing approximately 1,600 retail locations. This integration creates a seamless journey for patients from prescription to medication fulfillment, enhancing convenience and access.
Investor Confidence and Future Outlook
The new funding round highlights strong investor conviction in Mevo's potential, with lead investor Prosus viewing healthcare as Brazil's next major digital frontier. The firm praised Mevo's central role in this transformation and its strong execution in simplifying care delivery. This investment signals confidence in the company's ability to scale its platform nationwide and lead the market.
Existing investors like Matrix share this optimistic outlook, reaffirming their support for the company's mission. The firm highlighted Mevo's impressive growth trajectory and its success in building a platform that organizes the entire patient journey. This continued backing from early partners underscores the company's consistent performance and market leadership.
Looking ahead, Mevo aims to leverage this new capital to further its mission of creating a deeply connected healthcare ecosystem. The company projects that its platform will be used to treat 20 million patients in 2026 alone. This ambitious goal reflects its strategy to use the e-prescription as a gateway to a broader range of integrated patient services.
This latest US$18 million investment marks a pivotal moment for Mevo, providing the necessary resources to accelerate its expansion. The funding will empower the company to enhance its platform, connecting more patients and providers across the healthcare journey. As a result, Mevo is well-positioned to solidify its leadership and drive the digital transformation of healthcare in Brazil.